N-heptyl-4-methylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-heptyl-4-methylbenzamide
• 化学式: C₁₅H₂₃NO
• 分子量: 233.35
• InChiKey: PRHRTVHVXHBXTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF<br/>[FR] CLASSE DE COMPOSÉS DE PLATINE POUR LE TRAITEMENT DU CANCER, ET SON PROCÉDÉ DE PRÉPARATION<br/>[ZH] 一类治疗癌症用的铂类化合物及其制备方法
  申请人：SHANGHAI HAIJU BIOLOGICAL TECH CO LTD

  公开号：WO2022052014A1

  公开（公告）日：2022-03-17

  一类新颖的式(I)所示的铂类化合物，以及它们作为药剂、特别是用于单独或联合治疗癌症，预防癌症的药剂的用途。实验证明所述新式铂类化合物具有优越的体内抗肿瘤作用，显著优于临床药物卡铂；并且显著地改善了铂类药物的水溶性，可以制成冻干粉或注射液，解决了临床上使用不方便的缺陷。综上所述，公布的铂类化合物，具有良好的临床应用前景。
• [EN] NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2010010190A1

  公开（公告）日：2010-01-28

  [1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6, transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.